Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00382018
Other study ID # CDR0000504319
Secondary ID S0500U10CA032102
Status Completed
Phase Phase 3
First received September 26, 2006
Last updated October 3, 2017
Start date October 2006
Est. completion date July 11, 2017

Study information

Verified date October 2017
Source Southwest Oncology Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Measuring blood levels of tumor cells may help in learning how well chemotherapy works to kill metastatic breast cancer cells and allow doctors to plan better treatment. When blood levels of tumor cells are high while receiving chemotherapy, it is not yet known whether it is more effective to change chemotherapy regimens at that time or wait until disease progression.

PURPOSE: This randomized phase III trial is studying treatment decision making based on blood levels of tumor cells in women with metastatic breast cancer receiving chemotherapy.


Description:

OBJECTIVES:

Primary

- Determine whether women with metastatic breast cancer and elevated circulating tumor cells (CTCs) (≥ 5 per 7.5 mL of whole blood) after 3 weeks of first-line chemotherapy derive increased overall survival from changing to an alternative chemotherapy regimen at the next course rather than waiting for clinical evidence of progressive disease before changing to an alternative chemotherapy regimen.

- Determine whether these patients derive increased progression-free survival (PFS) from changing to an alternative chemotherapy regimen at the next course rather than waiting for clinical evidence of progressive disease before changing to an alternative chemotherapy regimen.

- Confirm previous findings that patients with < 5 CTCs per 7.5 mL of whole blood on initial screening have longer median OS and PFS than patients with ≥ 5 CTCs per 7.5 mL of whole blood.

- Determine the prognostic value of sequentially collected CTC values in these patients.

- Compare toxicity between patients with and without elevated CTCs after 3 weeks of first-line chemotherapy AND between the two randomized treatment arms.

Secondary

- Compare the prognostic and predictive value of CTC number vs breast cancer tumor markers, including CA 15-3 and carcinoembryonic antigen.

- Create a serum specimen bank for future biologic investigation.

OUTLINE: This is a partially blinded, partially randomized, multicenter study. Patients are assigned to 1 of 3 groups based on circulating tumor cells (CTCs) after 1 course of chemotherapy.

All patients undergo blood collection before their first dose of first-line chemotherapy* to determine baseline CTC count. Patients with < 5 CTCs at baseline are assigned to group I. Patients with ≥ 5 CTCs at baseline undergo a second blood draw on day 22 (after completion of 1 course of chemotherapy). Patients with < 5 CTCs after completing 1 course of chemotherapy are assigned to group 2. Patients with ≥ 5 CTCs after completion of 1 course of chemotherapy are assigned to group 3.

NOTE: *Chemotherapy may be initiated while waiting for the baseline CTC result.

- Group 1 (low risk of early progression): Patients continue to receive regular treatment without change at the discretion of the physician. Patients are eligible for other first-line chemotherapy trials. No further blood is collected.

- Group 2 (moderate risk of early progression): Patients continue to receive their current chemotherapy regimen without change.

- Group 3 (high risk of early progression): Patients are stratified according to HER-2 status (positive vs negative) and disease type (bone-only vs measurable disease). Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients continue with their current chemotherapy regimen without change.

- Arm II: Patients switch to a different chemotherapy regimen. Selection of a new chemotherapy regimen is made by the patient's doctor.

Patients receiving hormonal therapy or biologic therapy and chemotherapy continue to receive the hormonal or biologic therapy unchanged regardless of CTC level.

In groups 2 and 3, blood is collected periodically during chemotherapy and then at the completion of chemotherapy. Samples are examined for CTCs via the CellSearch™ blood test. Blood is also tested for CA 15-3 and carcinoembryonic antigen (CEA).

After completion of study therapy, patients are followed for up to 5 years.

PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 624
Est. completion date July 11, 2017
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed breast cancer

- Clinical evidence of metastatic disease (stage IV disease)

- Newly metastatic disease OR progressive metastatic disease while on hormonal therapy

- Meets 1 of the following criteria:

- Measurable disease

- Bone-only disease* NOTE: *Patients with nonmeasurable disease that does not include bone are not eligible

- HER-2 status determined by immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH) assay

- HER-2 positivity is defined as IHC 3+ or FISH+

- If IHC is indeterminate (2+), FISH must be performed to classify disease

- Planning to undergo first-line chemotherapy for metastatic disease

- Patients with brain metastases must have stable disease for > 90 days after completion of prior radiotherapy to the brain

- No leptomeningeal disease

- Hormone receptor status not specified

PATIENT CHARACTERISTICS:

- Female

- Menopausal status not specified

- Zubrod performance status 0-2

- Not pregnant or nursing

- Negative pregnancy test

- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or stage I or II cancer currently in complete remission

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Prior hormonal therapy, bisphosphonate therapy, trastuzumab (Herceptin®), and/or bevacizumab for metastatic disease allowed

- Any number of exogenous hormonal therapies for metastatic disease and/or as adjuvant therapy allowed

- At least 1 year since prior adjuvant chemotherapy

- At least 2 weeks since prior minor surgery and recovered

- At least 4 weeks since prior major surgery and recovered

- No prior chemotherapy for metastatic disease

- Concurrent hormonal therapy and/or bisphosphonate therapy allowed

- Concurrent trastuzumab and/or bevacizumab allowed

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
chemotherapy
No administration details available

Locations

Country Name City State
United States Kapiolani Medical Center at Pali Momi 'Aiea Hawaii
United States Hickman Cancer Center at Bixby Medical Center Adrian Michigan
United States San Luis Valley Regional Medical Center Alamosa Colorado
United States Hematology Oncology Associates, PC Albuquerque New Mexico
United States Lovelace Medical Center - Downtown Albuquerque New Mexico
United States Presbyterian Cancer Treatment Center at Presbyterian Kaseman Hospital Albuquerque New Mexico
United States University of New Mexico Cancer Center Albuquerque New Mexico
United States American Fork Hospital American Fork Utah
United States McFarland Clinic, PC Ames Iowa
United States Island Hospital Cancer Care Center at Island Hospital Anacortes Washington
United States Alaska Regional Hospital Cancer Center Anchorage Alaska
United States Providence Cancer Center Anchorage Alaska
United States CCOP - Michigan Cancer Research Consortium Ann Arbor Michigan
United States Saint Joseph Mercy Cancer Center Ann Arbor Michigan
United States University of Michigan Comprehensive Cancer Center Ann Arbor Michigan
United States Regional Medical Center Anniston Alabama
United States Rush-Copley Cancer Care Center Aurora Illinois
United States University of Colorado Cancer Center at UC Health Sciences Center Aurora Colorado
United States Alvin and Lois Lapidus Cancer Institute at Sinai Hospital Baltimore Maryland
United States Battle Creek Health System Cancer Care Center Battle Creek Michigan
United States Bay Regional Medical Center Bay City Michigan
United States Cleveland Clinic Beachwood Family Health and Surgery Center Beachwood Ohio
United States St. Joseph Cancer Center Bellingham Washington
United States St. Charles Medical Center - Bend Bend Oregon
United States Mecosta County Medical Center Big Rapids Michigan
United States Billings Clinic - Downtown Billings Montana
United States CCOP - Montana Cancer Consortium Billings Montana
United States Hematology-Oncology Centers of the Northern Rockies - Billings Billings Montana
United States St. Vincent Healthcare Cancer Care Services Billings Montana
United States Bismarck Cancer Center Bismarck North Dakota
United States Medcenter One Hospital Cancer Care Center Bismarck North Dakota
United States Mid Dakota Clinic, PC Bismarck North Dakota
United States St. Alexius Medical Center Cancer Center Bismarck North Dakota
United States Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center Boise Idaho
United States Central Care Cancer Center at Carrie J. Babb Cancer Center Bolivar Missouri
United States Wood County Oncology Center Bowling Green Ohio
United States Bozeman Deaconess Cancer Center Bozeman Montana
United States Olympic Hematology and Oncology Bremerton Washington
United States Roswell Park Cancer Institute Buffalo New York
United States Highline Medical Center Cancer Center Burien Washington
United States Fairview Ridges Hospital Burnsville Minnesota
United States St. James Healthcare Cancer Care Butte Montana
United States Southeast Cancer Center Cape Girardeau Missouri
United States Sandra L. Maxwell Cancer Center Cedar City Utah
United States Providence Centralia Hospital Centralia Washington
United States Roper St. Francis Cancer Center at Roper Hospital Charleston South Carolina
United States Louis A. Weiss Memorial Hospital Chicago Illinois
United States Resurrection Medical Center Chicago Illinois
United States Clackamas Radiation Oncology Center Clackamas Oregon
United States Cleveland Clinic Cancer Center at Fairview Hospital Cleveland Ohio
United States Cleveland Clinic Taussig Cancer Center Cleveland Ohio
United States Mercy and Unity Cancer Center at Mercy Hospital Coon Rapids Minnesota
United States Bay Area Hospital Coos Bay Oregon
United States Danville Regional Medical Center Danville Virginia
United States Oakwood Cancer Center at Oakwood Hospital and Medical Center Dearborn Michigan
United States Veterans Affairs Medical Center - Denver Denver Colorado
United States Barbara Ann Karmanos Cancer Institute Detroit Michigan
United States Josephine Ford Cancer Center at Henry Ford Hospital Detroit Michigan
United States Duke Cancer Institute Durham North Carolina
United States Cancer Centers of the Carolinas - Easley Easley South Carolina
United States CCOP - Hematology-Oncology Associates of Central New York East Syracuse New York
United States Fairview Southdale Hospital Edina Minnesota
United States Shaw Regional Cancer Center Edwards Colorado
United States Elkhart Clinic, LLC Elkhart Indiana
United States Elkhart General Hospital Elkhart Indiana
United States Michiana Hematology-Oncology, PC - Elkhart Elkhart Indiana
United States Elmhurst Memorial Hospital Elmhurst Illinois
United States Community Cancer Center Elyria Ohio
United States Hematology Oncology Center Elyria Ohio
United States Ephrata Cancer Center at Ephrata Community Hospital Ephrata Pennsylvania
United States Green Bay Oncology, Limited - Escanaba Escanaba Michigan
United States St. Francis Hospital Federal Way Washington
United States Genesys Hurley Cancer Institute Flint Michigan
United States Hurley Medical Center Flint Michigan
United States Fredericksburg Oncology, Incorporated Fredericksburg Virginia
United States Mercy and Unity Cancer Center at Unity Hospital Fridley Minnesota
United States Glendale Memorial Hospital Comprehensive Cancer Center Glendale California
United States Valley View Hospital Cancer Center Glenwood Springs Colorado
United States Wayne Memorial Hospital, Incorporated Goldsboro North Carolina
United States Altru Cancer Center at Altru Hospital Grand Forks North Dakota
United States St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center Grand Junction Colorado
United States Butterworth Hospital at Spectrum Health Grand Rapids Michigan
United States CCOP - Grand Rapids Grand Rapids Michigan
United States Lacks Cancer Center at Saint Mary's Health Care Grand Rapids Michigan
United States Three Rivers Community Hospital Grants Pass Oregon
United States Big Sky Oncology Great Falls Montana
United States Great Falls Clinic - Main Facility Great Falls Montana
United States Sletten Cancer Institute at Benefis Healthcare Great Falls Montana
United States Green Bay Oncology, Limited at St. Mary's Hospital Green Bay Wisconsin
United States Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center Green Bay Wisconsin
United States St. Mary's Hospital Medical Center - Green Bay Green Bay Wisconsin
United States St. Vincent Hospital Regional Cancer Center Green Bay Wisconsin
United States California Cancer Care, Incorporated - Greenbrae Greenbrae California
United States Cancer Centers of the Carolinas - Faris Road Greenville South Carolina
United States Cancer Centers of the Carolinas - Grove Commons Greenville South Carolina
United States CCOP - Greenville Greenville South Carolina
United States Greenville Hospital Cancer Center Greenville South Carolina
United States Cancer Centers of the Carolinas - Greer Medical Oncology Greer South Carolina
United States Van Elslander Cancer Center at St. John Hospital and Medical Center Grosse Pointe Woods Michigan
United States Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center Hartford Connecticut
United States Ingalls Cancer Care Center at Ingalls Memorial Hospital Harvey Illinois
United States Northern Montana Hospital Havre Montana
United States St. Peter's Hospital Helena Montana
United States Pardee Memorial Hospital Hendersonville North Carolina
United States Cancer Research Center of Hawaii Honolulu Hawaii
United States Hawaii Medical Center - East Honolulu Hawaii
United States Kapiolani Medical Center for Women and Children Honolulu Hawaii
United States OnCare Hawaii, Incorporated - Kuakini Honolulu Hawaii
United States OnCare Hawaii, Incorporated - Lusitana Honolulu Hawaii
United States Queen's Cancer Institute at Queen's Medical Center Honolulu Hawaii
United States Straub Clinic and Hospital, Incorporated Honolulu Hawaii
United States Tripler Army Medical Center Honolulu Hawaii
United States M. D. Anderson Cancer Center at University of Texas Houston Texas
United States Hutchinson Area Health Care Hutchinson Minnesota
United States Cleveland Clinic Cancer Center Independence Ohio
United States Community Regional Cancer Care at Community Hospital North Indianapolis Indiana
United States St. Vincent Indianapolis Hospital Indianapolis Indiana
United States Dickinson County Healthcare System Iron Mountain Michigan
United States Foote Memorial Hospital Jackson Michigan
United States University of Mississippi Cancer Clinic Jackson Mississippi
United States West Tennessee Cancer Center at Jackson-Madison County General Hospital Jackson Tennessee
United States Goldschmidt Cancer Center Jefferson City Missouri
United States NEA Medical Center - Stadium Boulevard Jonesboro Arkansas
United States Borgess Medical Center Kalamazoo Michigan
United States Bronson Methodist Hospital Kalamazoo Michigan
United States West Michigan Cancer Center Kalamazoo Michigan
United States Glacier Oncology, PLLC Kalispell Montana
United States Kalispell Medical Oncology at KRMC Kalispell Montana
United States Kalispell Regional Medical Center Kalispell Montana
United States Good Samaritan Cancer Center at Good Samaritan Hospital Kearney Nebraska
United States Columbia Basin Hematology Kennewick Washington
United States Kinston Medical Specialists Kinston North Carolina
United States Howard Community Hospital Kokomo Indiana
United States Gundersen Lutheran Center for Cancer and Blood La Crosse Wisconsin
United States Center for Cancer Therapy at LaPorte Hospital and Health Services La Porte Indiana
United States Breslin Cancer Center at Ingham Regional Medical Center Lansing Michigan
United States Sparrow Regional Cancer Center Lansing Michigan
United States University of New Mexico Cancer Center - South Las Cruces New Mexico
United States Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center Lebanon New Hampshire
United States Lima Memorial Hospital Lima Ohio
United States St. Rita's Medical Center Lima Ohio
United States St. Mary Mercy Hospital Livonia Michigan
United States Logan Regional Hospital Logan Utah
United States Loma Linda University Cancer Institute at Loma Linda University Medical Center Loma Linda California
United States USC/Norris Comprehensive Cancer Center and Hospital Los Angeles California
United States Southeastern Regional Medical Center Lumberton North Carolina
United States Holy Family Memorial Medical Center Cancer Care Center Manitowoc Wisconsin
United States HealthEast Cancer Care at St. John's Hospital Maplewood Minnesota
United States Minnesota Oncology Hematology, PA - Maplewood Maplewood Minnesota
United States Bay Area Cancer Care Center at Bay Area Medical Center Marinette Wisconsin
United States Northwest Ohio Oncology Center Maumee Ohio
United States Hillcrest Cancer Center at Hillcrest Hospital Mayfield Heights Ohio
United States Dubs Cancer Center at Rogue Valley Medical Center Medford Oregon
United States Providence Cancer Center at PMCC Medford Oregon
United States Saint Anthony Memorial Health Centers Michigan City Indiana
United States Providence Milwaukie Hospital Milwaukie Oregon
United States Hennepin County Medical Center - Minneapolis Minneapolis Minnesota
United States Virginia Piper Cancer Institute at Abbott - Northwestern Hospital Minneapolis Minnesota
United States Michiana Hematology-Oncology, PC - South Bend Mishawaka Indiana
United States Saint Joseph Regional Medical Center Mishawaka Indiana
United States Montana Cancer Center at St. Patrick Hospital and Health Sciences Center Missoula Montana
United States Montana Cancer Specialists at Montana Cancer Center Missoula Montana
United States Community Cancer Center of Monroe Monroe Michigan
United States Mercy Memorial Hospital - Monroe Monroe Michigan
United States Montrose Memorial Hospital Cancer Center Montrose Colorado
United States Clemens Regional Medical Center Mount Clemens Michigan
United States Skagit Valley Hospital Cancer Care Center Mount Vernon Washington
United States Camino Medical Group - Treatment Center Mountain View California
United States Cancer Center at Ball Memorial Hospital Muncie Indiana
United States Jon and Karen Huntsman Cancer Center at Intermountain Medical Center Murray Utah
United States Mercy General Health Partners Muskegon Michigan
United States Saint Peter's University Hospital New Brunswick New Jersey
United States Yale Cancer Center New Haven Connecticut
United States Newark Beth Israel Medical Center Newark New Jersey
United States UMDNJ University Hospital Newark New Jersey
United States Providence Newberg Medical Center Newberg Oregon
United States Fisher-Titus Medical Center Norwalk Ohio
United States Green Bay Oncology, Limited - Oconto Falls Oconto Falls Wisconsin
United States Val and Ann Browning Cancer Center at McKay-Dee Hospital Center Ogden Utah
United States Providence St. Peter Hospital Regional Cancer Center Olympia Washington
United States St. Charles Mercy Hospital Oregon Ohio
United States Toledo Clinic - Oregon Oregon Ohio
United States Willamette Falls Hospital Oregon City Oregon
United States Florida Hospital Cancer Institute at Florida Hospital Orlando Orlando Florida
United States Granville Medical Center Oxford North Carolina
United States Palo Alto Medical Foundation Palo Alto California
United States Parma Community General Hospital Parma Ohio
United States Regional Cancer Center at Singing River Hospital Pascagoula Mississippi
United States St. Joseph's Hospital and Medical Center Paterson New Jersey
United States Fox Chase Cancer Center - Philadelphia Philadelphia Pennsylvania
United States Cancer Center at Phoenixville Hospital Phoenixville Pennsylvania
United States UPMC Cancer Centers Pittsburgh Pennsylvania
United States Michiana Hematology Oncology PC - Plymouth Plymouth Indiana
United States St. Joseph Mercy Oakland Pontiac Michigan
United States Mercy Regional Cancer Center at Mercy Hospital Port Huron Michigan
United States CCOP - Columbia River Oncology Program Portland Oregon
United States Mercy Hospital Portland Maine
United States Providence Cancer Center at Providence Portland Medical Center Portland Oregon
United States Providence St. Vincent Medical Center Portland Oregon
United States Harrison Poulsbo Hematology and Onocology Poulsbo Washington
United States Utah Valley Regional Medical Center - Provo Provo Utah
United States Good Samaritan Cancer Center Puyallup Washington
United States Duke Health Raleigh Hospital Raleigh North Carolina
United States McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center Reading Pennsylvania
United States Spectrum Health Reed City Hospital Reed City Michigan
United States Virginia Cancer Institute - West End Richmond Virginia
United States Humphrey Cancer Center at North Memorial Outpatient Center Robbinsdale Minnesota
United States Swedish-American Regional Cancer Center Rockford Illinois
United States Person Memorial Hospital Roxboro North Carolina
United States William Beaumont Hospital - Royal Oak Campus Royal Oak Michigan
United States Seton Cancer Institute at Saint Mary's - Saginaw Saginaw Michigan
United States CentraCare Clinic - River Campus Saint Cloud Minnesota
United States Coborn Cancer Center Saint Cloud Minnesota
United States Dixie Regional Medical Center - East Campus Saint George Utah
United States Lakeland Regional Cancer Care Center - St. Joseph Saint Joseph Michigan
United States Lakeside Cancer Specialists, PLLC Saint Joseph Michigan
United States Comprehensive Cancer Care, PC Saint Louis Missouri
United States Missouri Baptist Cancer Center Saint Louis Missouri
United States CCOP - Metro-Minnesota Saint Louis Park Minnesota
United States Park Nicollet Cancer Center Saint Louis Park Minnesota
United States Regions Hospital Cancer Care Center Saint Paul Minnesota
United States United Hospital Saint Paul Minnesota
United States Tammy Walker Cancer Center at Salina Regional Health Center Salina Kansas
United States LDS Hospital Salt Lake City Utah
United States Utah Cancer Specialists at UCS Cancer Center Salt Lake City Utah
United States Cancer Therapy and Research Center San Antonio Texas
United States University Hospital - San Antonio San Antonio Texas
United States University of Texas Health Science Center at San Antonio San Antonio Texas
United States Veterans Affairs Medical Center - San Antonio (Murphy) San Antonio Texas
United States North Coast Cancer Care, Incorporated Sandusky Ohio
United States Guthrie Cancer Center at Guthrie Clinic Sayre Sayre Pennsylvania
United States Hematology and Oncology Associates of Northeastern Pennsylvania Scranton Pennsylvania
United States Fred Hutchinson Cancer Research Center Seattle Washington
United States Group Health Central Hospital Seattle Washington
United States Harborview Medical Center Seattle Washington
United States Minor and James Medical, PLLC Seattle Washington
United States Swedish Cancer Institute at Swedish Medical Center - First Hill Campus Seattle Washington
United States University Cancer Center at University of Washington Medical Center Seattle Washington
United States North Puget Oncology at United General Hospital Sedro-Woolley Washington
United States Cancer Centers of the Carolinas - Seneca Seneca South Carolina
United States St. Francis Cancer Center at St. Francis Medical Center Shakopee Minnesota
United States St. Nicholas Hospital Sheboygan Wisconsin
United States Welch Cancer Center at Sheridan Memorial Hospital Sheridan Wyoming
United States Mercy Medical Center - Sioux City Sioux City Iowa
United States Siouxland Hematology-Oncology Associates, LLP Sioux City Iowa
United States St. Luke's Regional Medical Center Sioux City Iowa
United States CCOP - Northern Indiana CR Consortium South Bend Indiana
United States Memorial Hospital of South Bend South Bend Indiana
United States Providence Cancer Institute at Providence Hospital - Southfield Campus Southfield Michigan
United States Cancer Centers of the Carolinas - Spartanburg Spartanburg South Carolina
United States Cancer Care Northwest - Spokane South Spokane Washington
United States Evergreen Hematology and Oncology, PS Spokane Washington
United States CCOP - Cancer Research for the Ozarks Springfield Missouri
United States Hulston Cancer Center at Cox Medical Center South Springfield Missouri
United States St. John's Regional Health Center Springfield Missouri
United States Stanford Cancer Center Stanford California
United States Lakeview Hospital Stillwater Minnesota
United States Cleveland Clinic Foundation - Strongsville Strongsville Ohio
United States Green Bay Oncology, Limited - Sturgeon Bay Sturgeon Bay Wisconsin
United States Flower Hospital Cancer Center Sylvania Ohio
United States Allenmore Hospital Tacoma Washington
United States CCOP - Northwest Tacoma Washington
United States Franciscan Cancer Center at St. Joseph Medical Center Tacoma Washington
United States MultiCare Regional Cancer Center at Tacoma General Hospital Tacoma Washington
United States St. Clare Hospital Tacoma Washington
United States CCOP - Scott and White Hospital Temple Texas
United States Albert Einstein Cancer Center at Albert Einstein College of Medicine The Bronx New York
United States Mercy Hospital of Tiffin Tiffin Ohio
United States CCOP - Toledo Community Hospital Toledo Ohio
United States Medical University of Ohio Cancer Center Toledo Ohio
United States St. Anne Mercy Hospital Toledo Ohio
United States St. Vincent Mercy Medical Center Toledo Ohio
United States Toledo Clinic, Incorporated - Main Clinic Toledo Ohio
United States Toledo Hospital Toledo Ohio
United States Cotton-O'Neil Cancer Center Topeka Kansas
United States Munson Medical Center Traverse City Michigan
United States Natalie Warren Bryant Cancer Center at St. Francis Hospital Tulsa Oklahoma
United States CCOP - Carle Cancer Center Urbana Illinois
United States Faxton Regional Cancer Center Utica New York
United States Pearlman Comprehensive Cancer Center at South Georgia Medical Center Valdosta Georgia
United States Southwest Washington Medical Center Cancer Center Vancouver Washington
United States Ridgeview Medical Center Waconia Minnesota
United States Maui Memorial Medical Center Wailuku Hawaii
United States Pacific Cancer Institute - Maui Wailuku Hawaii
United States St. John Macomb Hospital Warren Michigan
United States Covenant Cancer Treatment Center Waterloo Iowa
United States Fulton County Health Center Wauseon Ohio
United States Oncology Alliance, SC - Milwaukee - West Wauwatosa Wisconsin
United States Wenatchee Valley Medical Center Wenatchee Washington
United States Michiana Hematology Oncology PC - La Porte Westville Indiana
United States Dickstein Cancer Treatment Center at White Plains Hospital Center White Plains New York
United States Willmar Cancer Center at Rice Memorial Hospital Willmar Minnesota
United States Minnesota Oncology Hematology, PA - Woodbury Woodbury Minnesota
United States Cleveland Clinic - Wooster Wooster Ohio
United States Saint Vincent Hospital at Worcester Medical Center Worcester Massachusetts

Sponsors (3)

Lead Sponsor Collaborator
Southwest Oncology Group Cancer and Leukemia Group B, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Correlation of CTC Levels With Breast Cancer Tumor Markers Baseline, Weeks 4, 8, 13, 25, 37 and at progression
Primary Overall Survival From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. Every 3 months until progression then every 6 months for 5 years or until death
Primary Progression-free Survival Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions every 3 months until progression. From date of registration to date of first documentation of progressive disease, death due to any cause or symptomatic deterioration, whichever occurs first, assessed up to five years.
Primary Progression Free Survival From date of registration to date of first documentation of progressive disease, death due to any cause or symptomatic deterioration, whichever occurs first. Patients last known to be alive and progression-free are censored at date of last contact. every 3 months until progression
Secondary Number of Patients With Adverse Events That Are Related to Study Drugs Adverse Events (AEs) are reported by CTCAE Version 3.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. Toxicity assessment was evaluated after 3 weeks, 6 weeks, and every 6 weeks thereafter until progression
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A